Antisoma to present at BIO CEO conference

10 February 2006, London, UK – Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that its Director of Communications, Dr Daniel Elger, will participate in a panel session entitled “Revisiting Cytotoxics with New Molecules” at the BIO CEO and Investor Conference on Tuesday 14 February at 9.00am EST at the Waldorf Astoria Hotel in New York.

Antisoma’s presentation will consider the potential to improve outcomes in patients receiving cytotoxic chemotherapy by co-treatment with the Company’s vascular disrupting agent, AS1404.

A webcast of the session will be available at http://ceo.bio.org/opencms/ceo/2006/index.jsp .
from 12 hours after the presentation.


Enquiries: Margherita Lupi +44 (0)20 8799 8200Communications Manager

Background on Antisoma
Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Antisoma has a broad strategic alliance with Roche to develop and commercialise products from its pipeline. Please visit www.antisoma.com for further information.

Contact Information

Margherita Lupi

Communications Manager

Antisoma

Contact via E-mail